Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HM-002-1005 Single Dose Study in Type 2 Diabetes
NCT06498284Phase 1Completed
- Sponsor
- Hua Medicine
- Start
- Apr 2024
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of HMS1005 in type 2 diabetes mellitus (T2DM) (4 cohorts), sponsored by Hua Medicine. Primary endpoints: Incidence of adverse events at 11 Days, Area under the plasma concentration versus time curve at 72 hours and 3 more. Started Apr 2024; status: completed.
02
Drugs
HMS1005
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06498284.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06498284.